Tennessee House Bill HB0112

Tennessee 2023-2024 Regular Session

• Introduced: 1/11/23
• Refer: 1/20/23

Caption

AN ACT to amend Tennessee Code Annotated, Title 56, Chapter 7, Part 23, relative to the Proton Therapy Access Act.

Impact

This legislation is poised to significantly impact state healthcare laws by formalizing and expanding coverage for proton therapy treatments, which have emerged as a critical option in oncological care. By mandating insurance reimbursement standards for such therapies, the bill addresses the often high costs associated with advanced cancer treatments, potentially improving outcomes for patients who require these specialized services. Furthermore, it aligns patient treatment options with the latest advancements in medical technology, thereby promoting better healthcare outcomes within the state.

Summary

House Bill 112, also known as the Proton Therapy Access Act, aims to enhance access to proton therapy for cancer patients under the state group insurance program. This bill mandates that coverage for hypofractionated proton therapy is provided on par with the coverage for Intensity Modulated Radiation Therapy (IMRT). Specifically, the bill requires that the aggregate amount paid for proton therapy must not exceed the average cost of IMRT treatment for delivering an equivalent biological effective dose for the same type of cancer. The intent is to ensure equitable treatment options for patients undergoing radiation therapy.

Conclusion

In conclusion, the Proton Therapy Access Act represents a pivotal shift in cancer treatment accessibility and insurance coverage in Tennessee. If passed, HB 112 would not only reinforce the state’s commitment to enhancing cancer treatment options but also necessitate ongoing dialogue about the cost implications and effectiveness of emerging technologies in healthcare.

Contention

While proponents of HB 112 argue that this will provide patients with necessary access to advanced cancer treatments, opponents express concerns regarding the financial implications for the state insurance program. Critics argue that the provisions might lead to increased costs, potentially affecting the overall funding and sustainability of the state insurance program. Moreover, some stakeholders have raised questions about the comparative effectiveness of hypofractionated proton therapy versus conventional IMRT, emphasizing the need for further research and clinical validation.